Real-world safety and effectiveness of avelumab in immune-compromised (IC) and non-IC patients with Merkel cell carcinoma (MCC): Results from a prospective German registry (MCC-TRIM)Jürgen Becker, Selma Ugurel, Friedegund Meier et al.|EJC Skin Cancer|2025Cited by 0
EE509 Healthcare Resource Utilization (HCRU) and Associated Costs in Patients With Advanced Merkel Cell Carcinoma (aMCC) in Germany: Analysis From the MCC TRIM Registry StudyHamid Mahmoudpour, Dina Oksen, Jürgen C. Becker et al.|Value in Health|2025Cited by 0